Intellia Therapeutics
NASDAQ · NTLA·Cambridge, MA·Small-cap·Phase 3
Clinical-stage genome editing company developing in vivo and ex vivo CRISPR/Cas9 therapies. Lead asset nexiguran ziclumeran (nex-z, NTLA-2001) is a Phase 3 in vivo CRISPR therapy for ATTR amyloidosis; lonkagaytamonin (NTLA-2002) is in Phase 3 for hereditary angioedema.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Intellia Therapeutics Corporate Presentation | Corporate overview | April 15, 2026 | 37 |